Drugs / BGB-3245
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06194877 | Apr 2024 → Mar 2025 | colorectal cancer, pancreatic ductal adenocarcinoma | MapKure, LLC | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05580770 | Feb 2023 → Jan 2025 | neoplasm | SpringWorks Therapeutics, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-04-17 | BeOne Medicines | Results MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023 beonemedicines.com ↗
We believe that our early clinical data supported the advancement into our selected expansion cohorts which are now underway. |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB-3245 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06194877 ↗ |
| Route | Oral | “BGB-3245 5mg administered orally” NCT05580770 ↗ |